Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Advances in Breast Radiology
share announcement

Advances in Breast Radiology

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 3449

Special Issue Editors

Dr. Maria Adele Marino

E-Mail Website
Guest Editor
Department of Biomedical Sciences and Morphologic and Functional Imaging, University of Messina, Messina, Italy
Interests: breast imaging; digital mammography; digital breast tomosynthesis; breast cancer; breast MRI; ultrasound; elastography; contrast-enhanced ultrasound; contrast-enhanced mammography
Dr. Elisabetta Giannotti

E-Mail Website
Guest Editor
Nottingham Breast Institute, Nottingham University Hospitals, Nottingham NG5 1PB, UK
Interests: breast imaging; digital mammography; digital breast tomosynthesis; breast cancer; breast MRI; ultrasound; elastography; contrast-enhanced ultrasound; contrast-enhanced mammography
Daly Avendano

E-Mail Website
Guest Editor Assistant
Tecnologico de Monterrey, School of Medicine and Health Science, Monterrey, Nuevo León, Mexico
Interests: breast imaging; digital mammography; digital breast tomosynthesis; breast cancer; breast MRI; ultrasound; elastography; contrast-enhanced ultrasound; contrast-enhanced mammography

Special Issue Information

Dear Colleagues, 

This Special Issue of Diagnostics is focused on Advances in Breast Radiology, with special interest in contrast-enhanced techniques used in the field of breast imaging. Contrast-enhanced MRI is an established tool for breast cancer detection and diagnosis, and much interest has recently been raised by the 2D counterpart (i.e., contrast-enhanced mammography), which has proved its diagnostic accuracy. Contrast-enhanced ultrasound is taking on an emerging role, although still limited. It is mainly used in the setting of multiparametric US protocols for breast cancer depiction. The aim of this Special Issue is to highlight the main advances in breast radiology, with particular attention to contrast-enhanced imaging and the possible implication of artificial intelligence in this specific field.

Dr. Maria Adele Marino
Dr. Elisabetta Giannotti
Guest Editors
Daly Avendano
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast contrast-enhanced MRI
  • breast contrast-enhanced US
  • breast contrast-enhanced mammography

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

12 pages, 2232 KiB  
Article
Prognostic Molecular Biomarkers in Breast Cancer Lesions with Non-Mass Enhancement on MR
by Mei-Lin Wang, Yu-Pin Chang, Chen-Hao Wu, Chuan-Han Chen, Mein-Kai Gueng, Yi-Ying Wu and Jyh-Wen Chai
Diagnostics 2024, 14(7), 747; https://doi.org/10.3390/diagnostics14070747 - 30 Mar 2024
Viewed by 609
Abstract
Clustered ring enhancement (CRE) is a new lexicon for non-mass enhancement (NME) of breast MR in the 5th BIRADS, indicating a high suspicion of malignancy. We wonder if the presence of CRE correlates with expression of prognostic molecular biomarkers of breast cancer. A [...] Read more.
Clustered ring enhancement (CRE) is a new lexicon for non-mass enhancement (NME) of breast MR in the 5th BIRADS, indicating a high suspicion of malignancy. We wonder if the presence of CRE correlates with expression of prognostic molecular biomarkers of breast cancer. A total of 58 breast lesions, which MRI reported with NME, were collected between July 2013 and December 2018. The patterns of enhancement including CRE were reviewed and the pathological results with expression of molecular biomarkers were collected. The association between MRI NME, pathological, and IHC stain findings were investigated under univariate analysis. A total of 58 breast lesions were pathologically proven to have breast cancer, comprising 31 lesions with CRE and 27 lesions without CRE on breast MRI. The expression of the estrogen receptor (ER) (p = 0.017) and the progesterone receptor (PR) (p = 0.017) was significantly lower in lesions with CRE as compared with those without CRE. The expression of Ki-67 (≥25%) was significantly higher in lesions with CRE (p = 0.046). The lesions with CRE had a lower expression ratio of ER (50.71 ± 45.39% vs. 74.26 ± 33.59%, p = 0.028). Our study indicated that lesions with CRE may possess different features from those without CRE in molecular expression, bearing a more aggressive behavior. Full article
(This article belongs to the Special Issue Advances in Breast Radiology)
►▼ Show Figures

Figure 1

Other

Jump to: Research

17 pages, 826 KiB  
Systematic Review
The Applications of High-Intensity Focused Ultrasound (HIFU) Ablative Therapy in the Treatment of Primary Breast Cancer: A Systematic Review
by Dania Zulkifli, Hanani Abdul Manan, Noorazrul Yahya and Hamzaini Abdul Hamid
Diagnostics 2023, 13(15), 2595; https://doi.org/10.3390/diagnostics13152595 - 04 Aug 2023
Cited by 7 | Viewed by 2300
Abstract
Background: This study evaluates the role of high-intensity focused ultrasound (HIFU) ablative therapy in treating primary breast cancer. Methods: PubMed and Scopus databases were searched according to the PRISMA guidelines to identify studies from 2002 to November 2022. Eligible studies were selected based [...] Read more.
Background: This study evaluates the role of high-intensity focused ultrasound (HIFU) ablative therapy in treating primary breast cancer. Methods: PubMed and Scopus databases were searched according to the PRISMA guidelines to identify studies from 2002 to November 2022. Eligible studies were selected based on criteria such as experimental study type, the use of HIFU therapy as a treatment for localised breast cancer with objective clinical evaluation, i.e., clinical, radiological, and pathological outcomes. Nine studies were included in this study. Results: Two randomised controlled trials and seven non-randomised clinical trials fulfilled the inclusion criteria. The percentage of patients who achieved complete (100%) coagulation necrosis varied from 17% to 100% across all studies. Eight of the nine studies followed the treat-and-resect protocol in which HIFU-ablated tumours were surgically resected for pathological evaluation. Most breast cancers were single, solitary, and palpable breast tumours. Haematoxylin and eosin stains used for histopathological evaluation showed evidence of coagulation necrosis. Radiological evaluation by MRI showed an absence of contrast enhancement in the HIFU-treated tumour and 1.5 to 2 cm of normal breast tissue, with a thin peripheral rim of enhancement indicative of coagulation necrosis. All studies did not report severe complications, i.e., haemorrhage and infection. Common complications related to HIFU ablation were local mammary oedema, pain, tenderness, and mild to moderate burns. Only one third-degree burn was reported. Generally, the cosmetic outcome was good. The five-year disease-free survival rate was 95%, as reported in two RCTs. Conclusions: HIFU ablation can induce tumour coagulation necrosis in localised breast cancer, with a favourable safety profile and cosmetic outcome. However, there is variable evidence of complete coagulation necrosis in the HIFU-treated tumour. Histopathological evidence of coagulation necrosis has been inconsistent, and there is no reliable radiological modality to assess coagulation necrosis confidently. Further exploration is needed to establish the accurate ablation margin with a reliable radiological modality for treatment and follow-up. HIFU therapy is currently limited to single, palpable breast tumours. More extensive and randomised clinical trials are needed to evaluate HIFU therapy for breast cancer, especially where the tumour is left in situ. Full article
(This article belongs to the Special Issue Advances in Breast Radiology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop